1. Home
  2. Labeler Index
  3. A-s Medication Solutions
  4. 50090-3889
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Levetiracetam NDC 50090-3889 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label Image - lbl500903889

Label Image - lbl500903889

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

The figure demonstrates the Responder Rate with a 250% Reduction from Baseline in Study 1, where the percentage ranges from 0% to 39.6%. The text mentions Leviaseam 000 oy and Leviaseam 100 ooy, suggesting the names of the products being evaluated. It also indicates that the results were statistically significant compared to the placebo.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

This is a chart showing the Responder Rate in Study 2 during Period A. The percentage of patients is shown on the Y-axis, ranging from 0% to 40%. The X-axis shows three types of treatments - Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. A statistically significant reduction in responder rate was observed with Levetiracetam 2000 mg/day compared to Placebo.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4 shows the responder rate with a 50% reduction from baseline in Study 4. The responder rate was 44.6% in the Levetiracetam group compared to 19.6% in the Placebo group (N=97, N=101 respectively). The difference between both groups was statistically significant.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5 shows the responder rate for patients between the ages of 1 month and < 4 years with a reduction of over 50% from baseline in Study 5. The graph shows that the responder rate was 190.6% for patients who received Lovetracatam while it was statistically significant versus the placebo control group.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

The text describes a figure (Figure 6) which shows a responder rate percentage and reduction in PGTC seizure frequency per week. The results suggest that there is a statistically significant reduction in seizures with the use of Levetiracetam compared to placebo.*

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.